Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Time to first treatment and optimal adjuvant treatment strategy in patients with resectable gastric cancer pathologically upstaged to lymph node–positive disease.
Authors
Pranay Shah Ajay
Emory University, Atlanta, GA;
Pranay Shah Ajay , Caitlin Sok , Subir Goyal , Jeffrey M. Switchenko , Felipe Maegawa , Theresa Wicklin Gillespie , Chrystal M Paulos , David A. Kooby , Timothy Kennedy , Mihir Maheshkumar Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Other
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 473)
DOI
10.1200/JCO.2023.41.4_suppl.473
Abstract #
473
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).
First Author: Masanori Terashima
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Reliability of computed tomography to determine the eligibility of conversion surgery for gastric cancer with para-aortic lymph node metastasis.
First Author: Takeyuki Wada
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of DNA mismatch repair status on prognosis of patients with locally advanced gastric cancer in a Mexican population.
First Author: Maria del Consuelo Diaz Romero
Poster
2023 ASCO Breakthrough
Immunonutrition supplementation for resectable gastric cancer during standard perioperative chemotherapy (CT) FLOT: A pivotal study, I–SUPPLY.
First Author: Valeria Pusceddu